The Board has initiated this review aiming to optimise shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector's lead asset Betalutin and implement a restructuring of the company.
Chair Jan H. Egberts commented: "The decision to discontinue the PARADIGME study was extremely disappointing. As a result, we are now focused on achieving an outcome for the company that creates maximum value for shareholders."
"We believe this should include exploring all strategic options and, as a leading financial advisor in the Nordic region, Carnegie is strongly positioned to help us achieve the best possible outcome for our shareholders and other stakeholders."
No assurances can be given as to the outcome or timing of the review process. Nordic Nanovector does not intend to make any further public comment regarding the review until it has been completed or the company determines that disclosure is required or appropriate.
Advokatfirmaet Selmer AS is acting as Nordic Nanovector's legal adviser.
